The global myopia and presbyopia treatment market was valued at USD 22.5 billion in 2025 and is projected to grow from USD 24.35 billion in 2026 to USD 46.35 billion by 2034, a compound annual growth rate of 8.38% over the forecast period. Contrive Datum Insights reports these figures in its study, "Myopia And Presbyopia Treatment Market Size, Share & Industry Analysis," which covers the market from 2026 to 2034.
The category addresses the two most common refractive vision disorders. Myopia, or nearsightedness, typically starts in childhood. Presbyopia, the age-related loss of near focus, reaches nearly every adult past midlife. Products run from everyday eyeglasses and contact lenses to intraocular lenses used in cataract and refractive procedures, plus emerging pharmacological and orthokeratology approaches meant to slow myopia progression in children. Buyers include individual patients shopping at optical retailers and online, and hospitals and surgery centers that procure implantable lenses and diagnostic equipment.
The strongest single driver is rising global myopia prevalence, led by pediatric onset in Asia Pacific. The study rates its impact high, and it bears most heavily on the fastest-growing type line. Other grows at 10.72% a year, lifting its share of revenue from 14% to 17% and its value from USD 3.15 billion to USD 7.88 billion.
Eyeglasses remain the largest type line, with 34% of 2025 revenue at USD 7.65 billion. They still hold 28% in 2034, yet grow at only 6.04%, well under the market rate. The other four axes show a similar split between the biggest lines and the quickest. By indication, Myopia leads with 46% of revenue at USD 10.35 billion, while Combined (Dual Condition) grows fastest at 9.21%. Hospitals & Specialty Eye Clinics account for 42% of end-user revenue at USD 9.45 billion, but Online / E-commerce expands at 12.26%. Among age groups, Presbyopic Adults (41-60 Years) hold 34.98% of revenue at USD 7.87 billion, and Geriatric (Above 60 Years) grows fastest at 10.57%. Out-of-Pocket Payment covers 48% of revenue at USD 10.8 billion; Public & Government Programs grows at 10.24%.
Asia Pacific is the largest region, taking 36% of 2025 revenue at USD 8.1 billion. Its share climbs to 40% by 2034, when revenue reaches USD 18.54 billion. Middle East and Africa stays the smallest region at 6% in both years. The United States is the largest single country market at USD 5.36 billion in 2025, or 23.82% of global revenue.
The forecast depends on two conditions. If premium-lens adoption slows because out-of-pocket cost sensitivity persists, and public reimbursement for elective vision correction expands more slowly than expected, 2034 revenue holds at USD 42.5 billion. Faster uptake of premium presbyopia-correcting IOLs and quicker rollout of publicly funded myopia-control programs in Asia Pacific school systems would lift it to USD 50.2 billion. The base case sits between the two at USD 46.35 billion.
The report segments the market across five axes (type, indication, end user, age group and payer type) with revenue and growth rates for every line in every year from 2020 to 2034. It covers all five regions with country-level breakdowns, the competitive landscape, and the research methodology behind each estimate. It is delivered as a PDF, and a free sample is available on request.